NCT00869323View on ClinicalTrials.gov

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

December 31, 2016

Conditions
Lymphoproliferative Disorder
Interventions
BIOLOGICAL

rituximab

375 mg/m\^2 intravenously on Days 1,8, 15 and 22

DRUG

bortezomib

1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22

Trial Locations (2)

55455

University of Minnesota Medical Center - Fairview, Minneapolis

63110

Washington University School of Medicine - Oncology Division, St Louis

Sponsors
All Listed Sponsors
collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00869323 - Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders | Biotech Hunter | Biotech Hunter